title: Glutamate receptor ion channel properties predict vulnerability to cytotoxicity in a transfected nonneuronal cell line.
abstract: Excessive activation of glutamate receptors is thought to play a critical role in neuronal excitotoxicity. To compare the cytotoxic potential of different glutamate receptor subtypes and correlate receptor biophysical properties with cytotoxicity, we have expressed recombinant receptors in human embryonic kidney 293 (HEK-293) cells. Survival of transfected cells was analyzed under conditions of defined agonist concentration and exposure time. For HEK-293 cells transfected with N-methyl-D-aspartate (NMDA) receptors, the EC50 for NMDA-induced cytotoxicity was 300 microM. Experiments using ion substitution, or cells expressing mutant NMDA receptors with low calcium permeability, suggested that both calcium and sodium influx through NMDA receptors contributed to cytotoxicity. In contrast, cytotoxicity was not observed in cells transfected with calcium permeable alpha-amino 3-hydroxy-5-methyl-4-isoxazole propionate- or kainate-type glutamate receptors even at saturating agonist concentrations, unless inhibitors of agonist-dependent desensitization were included. These results directly demonstrate that calcium permeability and desensitization kinetics play important roles in determining the excitotoxic potential of different glutamate receptor subtypes.
authors.affiliation: Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, Canada.
authors.forename: L A
authors.initials: LA
authors.lastname: Raymond
authors.forename: A
authors.initials: A
authors.lastname: Moshaver
authors.forename: W G
authors.initials: WG
authors.lastname: Tingley
authors.forename: R L
authors.initials: RL
authors.lastname: Huganir
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D001483:Base Sequence; D001581:Benzothiadiazines / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003208:Concanavalin A / Q000494:pharmacology; D017931:DNA Primers; D016291:Dizocilpine Maleate / Q000494:pharmacology; D005071:Evoked Potentials / Q000187:drug effects*; D018698:Glutamic Acid / Q000494:pharmacology; D006801:Humans; D007473:Ion Channels / Q000096:biosynthesis / Q000502:physiology*; D007608:Kainic Acid / Q000633:toxicity*; D007668:Kidney; D051379:Mice; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D016202:N-Methylaspartate / Q000633:toxicity*; D009498:Neurotoxins / Q000633:toxicity*; D018408:Patch-Clamp Techniques; D017470:Receptors, Glutamate / Q000096:biosynthesis / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000096:biosynthesis / Q000187:drug effects / Q000502:physiology*; D014162:Transfection
chemical_list: D001581:Benzothiadiazines; D017931:DNA Primers; D007473:Ion Channels; D009498:Neurotoxins; D017470:Receptors, Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D003208:Concanavalin A; D018698:Glutamic Acid; D016202:N-Methylaspartate; D016291:Dizocilpine Maleate; D015763:2-Amino-5-phosphonovalerate; C004639:cyclothiazide; D007608:Kainic Acid